Neogenomics Inc is a leading provider of cancer-focused genetic testing and diagnostic services
The company specializes in developing advanced technologies that enhance the accuracy of cancer diagnosis and treatment planning. Through its comprehensive suite of laboratory services, Neogenomics aids healthcare providers by offering insights into genetic markers associated with various cancers, enabling personalized medicine approaches. In addition to its testing services, Neogenomics is dedicated to research and development, striving to improve and innovate methodologies that contribute to better patient outcomes in oncology.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 6.3%. This performance is a noticeable divergence from the S&P 500’s 5.1% return.
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQNEO), a leading oncology testing services company, today announced the Company will participate in the following investor conferences:
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQNEO)
fell 21.5% in the afternoon session after the company reported weak fourth-quarter results, with revenue falling below Wall Street's expectations. Also, the result revealed minimal bottom-line improvement, as the business remained unprofitable. Further weighing on results, the company posted negative free cash flow for the quarter.
On the other hand, guidance was more encouraging as full-year sales and EBITDA outlook were both ahead of consensus estimates. Overall, this was a challenging quarter.
Oncology (cancer) diagnostics company NeoGenomics (NASDAQNEO) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 10.6% year on year to $172 million. On the other hand, the company’s full-year revenue guidance of $740 million at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $0.04 per share was $0.01 above analysts’ consensus estimates.
NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading oncology testing services company, today announced its fourth-quarter and full year results for the period ended December 31, 2024.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Tuesday, February 18, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQNEO), a leading oncology testing services company, today provided financial guidance for fiscal year 2025 and updated its Long-Range Financial Plan.
Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQNEO), a leading oncology testing services company, today announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025. Tony Zook, an independent board member since 2023, will assume the role of CEO at that time.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Chris Smith, Chief Executive Officer, will deliver a presentation followed by Q&A on Wednesday, January 15, at 1:30 p.m. PT/4:30 p.m. ET.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, announced the recent publication of a new study in ESMO Open, demonstrating how circulating tumor DNA (ctDNA) in monitoring molecular residual disease (MRD) may enable earlier identification of disease recurrence for high-risk melanoma patients.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will share its latest research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary central nervous system (CNS) lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting, booth #2347, in San Diego, December 7-10. The company will also feature its robust hematological oncology solutions, including COMPASS, AML Express, and AML MRD Flow Panel.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo in Vancouver, Canada, November 19-23 (booth #830). The research demonstrates how ctDNA and next-generation sequencing (NGS) can drive more personalized and accurate treatment options for cancer patients.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will attend the Piper Sandler 36th Annual Healthcare Conference. Members of the management team will participate in an in-person fireside chat on Thursday, Dec. 5, 2024, at 9:30 a.m. ET in New York City.
